



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUNE 21, 2019

PTAS

CHARLES P. LANDRUM, NORTON ROSE
FULBRIGHT US LLP
98 SAN JACINTO BOULEVARD
SUITE 1100
AUSTIN, TX 78701-4255

505536542

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/20/2019

REEL/FRAME: 049542/0895

NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: XERP.P0058US.P1

ASSIGNOR:
DONOVAN, MARTIN

DOC DATE: 06/11/2019

ASSIGNOR:
HU, WENDY

DOC DATE: 06/11/2019

ASSIGNEE:
XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET
SUITE 1600
CHICAGO, ILLINOIS 60601

APPLICATION NUMBER: 62855134

FILING DATE: 05/31/2019

PATENT NUMBER:

ISSUE DATE:

TITLE: STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND
METHODS OF MANUFACTURING THE SAME

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5583339

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARTIN DONOVAN	06/11/2019
WENDY HU	06/11/2019
RECEIVING PARTY DATA	
Name:	XERIS PHARMACEUTICALS, INC.
Street Address:	180 N. LASALLE STREET
Internal Address:	SUITE 1600
City:	CHICAGO
State/Country:	ILLINOIS
Postal Code:	60601
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	62855134
CORRESPONDENCE DATA	
Fax Number:	(512)536-4598
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5124745201
Email:	sharon.dunn@nortonrosefulbright.com
Correspondent Name:	CHARLES P. LANDRUM, NORTON ROSE FULBRIGHT US LLP
Address Line 1:	98 SAN JACINTO BOULEVARD
Address Line 2:	SUITE 1100
Address Line 4:	AUSTIN, TEXAS 78701-4255
ATTORNEY DOCKET NUMBER:	XERP.P0058US.P1
NAME OF SUBMITTER:	CHARLES P. LANDRUM
SIGNATURE:	/Charles P. Landrum/
DATE SIGNED:	06/20/2019
Total Attachments: 1	
source=XERP_P0058US_P1_Assign#page1.tif	

A S S I G N M E N T

WHEREAS, the undersigned (individually "**ASSIGNOR**" and collectively "**ASSIGNORS**"), are named inventors of the patent(s)/application(s) identified below (collectively "**Patent(s)**"),

AND WHEREAS Xeris Pharmaceuticals, Inc. , having a place of business at 180 N. LaSalle Street, Suite 1600, Chicago, IL 60601 ("**ASSIGNEE**"), is desirous of acquiring all right, title and interest in and to the Patent(s);

FOR GOOD AND VALUABLE CONSIDERATION, the receipt, sufficiency and adequacy of which are hereby acknowledged, each ASSIGNOR does hereby:

IRREVOCABLY SELLS, ASSIGNS, AND TRANSFERS to the ASSIGNEE ASSIGNOR's entire right, title, interest throughout the world in, and right to claim priority to U.S. Provisional Patent Application No. **62/855,134**, filed **May 31, 2019**, titled "**STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAME**", including all information disclosed therein, such right, title, and interest including but not limited to the right to sue for injunctions and/or damages for any past, ongoing, and/or future infringement. For the avoidance of doubt, this sale, assignment, and transfer extends to all ASSIGNOR's right, title, interest in, and right to claim priority to all patents and applications (throughout the world) of any kind that claim priority to or otherwise issue from any of the Patent(s), including any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents and/or patent applications;

WARRANTS AND COVENANTS that ASSIGNOR has the authority to enter this ASSIGNMENT agreement, and that ASSIGNOR has done nothing and will not do anything to impair the rights conveyed to ASSIGNEE by this Agreement;


COVENANTS that, when requested and at the expense of the ASSIGNEE, ASSIGNOR will carry out in good faith the intent and purpose of this Agreement, including but not limited to executing any and all documents in connection with the Patent(s) and any and all divisional, continuation, continuation-in-part, continuing, extension, foreign, international, national phase, non-provisional, provisional, reexamination, reissue, renewal or substitute patents, and/or patent applications claiming priority to, or based on any information disclosed in any of the Patent(s), including all rightful oaths, declarations, assignments, powers of attorney, and other papers; communicate to the ASSIGNEE all facts known to the ASSIGNOR relating to all information disclosed in the Patent(s) and the history thereof; and generally do everything possible that the ASSIGNEE shall consider desirable for vesting title to the Patent(s) and such patents and/or patent applications in the ASSIGNEE, and for securing, maintaining, and enforcing patent protection for the Patent(s) and such patents and/or patent applications;


WAIVES any right it has to challenge the adequacy of the consideration; and

AGREES that this Agreement is binding on ASSIGNOR's heirs, assigns, representatives, and successors.

ASSIGNEE


Name: **Martin DONOVAN**
Date: 11 Jun 2019


Name: **Wendy HU**
Date: 11 Jun 2019


Name: _____ Date: June 12, 2019

Title: SVP, General Counsel and Corporate Secretary

For: Xeris Pharmaceuticals, Inc.